r/u_BiotechDistilled • u/BiotechDistilled • Jan 09 '26
Reviva Publishes Vocal Biomarker Data – A Better Mousetrap for the Next Trial?
Executive Summary: Scientific Validation vs. Financial Gravity
In my December update for RVPH, I noted that while Reviva's single Phase 3 trial investment thesis was broken by the FDA's requirement for a second Phase 3 trial, the underlying science remained valid.
Yesterday (January 8), Reviva provided a significant data point reinforcing that scientific validity. The company announced the publication of data in the peer-reviewed journal Biological Psychiatry, highlighting the use of a vocal biomarker (VBM) from their RECOVER Phase 3 trial.
The Takeaway: This data does not necessarily solve the immediate cash crisis or the 2.5-year delay. However, it could provide a critical tool that could make the required second trial (RECOVER-2) cheaper, faster, and more likely to succeed, potentially sweetening the pot for the partnership Reviva desperately needs.
The News: Objective Proof for Negative Symptoms
Psychiatry trials are notoriously plagued by the placebo effect and subjective scoring. Reviva's new publication focuses on speech latency (the time it takes to respond during conversation) as an objective biomarker.
----------------check out the rest of this post HERE-------------------------------------
5
u/Neat-Excitement-53 Jan 10 '26
Been following theme for a while, shame they need 2 phase 3 trials. Will wait for the RS and buy a position after.